Category: Prostate Cancer

Governor Brown to Get Further Prostate Cancer Treatment

Brown’s oncologist, Dr. Eric Small of the University of California, San Francisco, says in the statement the disease is not extensive and can be treated with “a short course of radiotherapy.” Brown’s office says he will continue his full work schedule through treatment, which is planned to occur between late February and early March.

Governor Brown to Get Further Prostate Cancer Treatment

Brown’s oncologist, Dr. Eric Small of the University of California, San Francisco, says in the statement the disease is not extensive and can be treated with “a short course of radiotherapy.” Brown’s office says he will continue his full work schedule through treatment, which is planned to occur between late February and early March.

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic…

In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen recurrent prostate cancer in hormone-naive and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose.

Mum urges others to ‘band together’ after son’s cancer

A Burgess Hill mum who went through the horror of finding out her 18-month-old son had cancer is urging others to back an international campaign to support the charity that helped her. Natasha Penney, from Burgess Hill, went through every parents’ worst nightmare when she found out her son, Seb, had bladder and prostate cancer in 2015.

“Dancing with the Stars” Co-Host Erin Andrews Reveals Battle with Cervical Cancer

Trump tells reporters in the Oval Office… — The governor of Minnesota, Mark Dayton, has prostate cancer, he said Tuesday.Dayton said that he learned of the diagnosis last week and that he might have… – Iran, Russia and Turkey agreed to launch a three-way mechanism to ensure compliance with the Syrian ceasefire as talks on the conflict concluded T… The American Soybean Association has communicated to the White House that the significant trade benefits U.S. farmers have achieved under the North American Free Trade A… A winter storm has blanketed parts of Western Nebraska and that means we’ve got postponements and/or cancellations for events today.

AroCell AB: Research poster on prostate cancer has been accepted by…

AroCell AB announces today that a research poster submitted by Kiran Kumar J et al entitled “The AroCell TK 210 ELISA may complement Pro PSA and the Prostate Health Index in differentiating pre-cancerous and cancerous conditions in prostate cancer” was accepted by the AARC for presentation at their annual meeting in April 2017. The purpose of this study was to compare the AroCell TK 210 ELISA with PSA, free PSA, pro PSA and PHI in men with pre-cancerous conditions and patients with confirmed prostate cancer.

Dr. Safana Salim Al Saidi, a chemical pathologist. – ” ONA

Muscat: A chemical pathologist in the Ministry of Health has succeeded in validating a new marker which helps in early prostate cancer diagnosis. Dr. Safana Salim Al Saidi, a chemical pathologist worked along with her team from the MoH, the Sultan Qaboos University Hospital and the Research Council , under the supervision of Dr. Waad Allah Mula, Professor at the Royal Hospital for Clinical Biochemistry.

Surrey Prostate Cancer Support Group hosts meeting Jan. 28

The organization holds supportive gatherings on the last Saturday of every month for men affected by prostate cancer and provides awareness, public education, advocacy, support and research into the prevention, detection, treatment and cure of prostate cancer. On Jan. 28, Dr. Michael Peacock from UBC Radiation Oncology will speak on Prostate Brachytherapy treatments and effects.

Far Fewer Men Being Treated for Prostate Cancer

The number of older Americans treated for prostate cancer plummeted 42 percent since health officials began questioning the benefits of screening tests, a new study shows. The finding points to the success of efforts to curtail the use of controversial prostate-specific antigen, or PSA, screening tests, said lead author Dr. Tudor Borza.

Prostate cancer (PC) Therapeutic and Drug Pipeline Review H2

PUNE, INDIA, January 16, 2017 / EINPresswire.com / — GET SAMPLE REPORT @ Summary Prostate cancer is a type of cancer that affects the prostate gland of the male reproductive system, and is the most common non-cutaneous malignant cancer in men. Internationally, it is the sixth-largest cancer-related cause of death in men.

Sanpower Release: Week in Review: China’s Company Pays $820 For…

Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world’s first immunotherapy, from Valeant Pharma . Approved as a treatment for prostate cancer in 2010, Dendreon never lived up to expectations because it combined high cost, limited insurance approvals and mediocre improvement over competitors.

This Is the Smartest Move Valeant Pharmaceuticals Has Made in a Really Long Time

As announced early Tuesday morning, Valeant is selling some $2.1 billion worth of its assets to help pay down the more than $30 billion in debt it ended with in the third quarter. Assuming both deals close as planned, and Valeant continues to shuffle a good chunk of its earnings before interest, taxes, depreciation, and amortization toward debt reduction, the company may be able to push its debt levels down near $27 billion to $27.5 billion by mid-2017.

Men with history of cancer more likely to develop aggressive strains: Aussie study

Australian researchers have discovered why men with a family history of prostate cancer develop a more aggressive strain of the disease. Researchers from Melbourne’s Monash University, in a joint research effort with a group of Australia’s most renowned cancer research institutes, revealed that the BRCA2 gene fault in conjunction with a family history of prostate cancer breeds an aggressive type of prostate cancer.

Researchers discover genetic fingerprint identifying how prostate cancer spreads

Canadian researchers have identified a genetic fingerprint that explains why up to almost a third of men with potentially curable localized prostate cancer develop aggressive disease that spreads following initial treatment. Co-principal investigator Dr. Robert Bristow of Toronto’s Princess Margaret Cancer Centre says the discovery could help doctors personalize more effective, targeted therapies from the moment a man is diagnosed with prostate cancer.

Prostate cancer genetics could aid cure: study

Canadian researchers have identified a genetic fingerprint that explains why up to almost a third of men with potentially curable localized prostate cancer develop aggressive disease that spreads following initial treatment. Co-principal investigator Dr. Robert Bristow of Toronto’s Princess Margaret Cancer Centre says the discovery could help doctors personalize more effective, targeted therapies from the moment a man is diagnosed with prostate cancer.

MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO

MDxHealth SA today provides a preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued strong growth of ConfirmMDxA and early adoption of SelectMDx for Prostate Cancer during the year. The Company previously upgraded its expected full-year revenue growth to more than 60% compared with its initial guidance predicting growth of 30-50% over 2015.

Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.

Cancer Supportive Care Products Market Worth US $31.7 Billion by 2021

The global cancer supportive care products market is projected to expand at a CAGR of 4.3% during the forecast period . Cancer supportive care products are mainly used in the treatment of adverse effects associated with cancer therapy as well as for treatment of symptoms and signs of cancer, such as chemotherapy-induced nausea and vomiting, chemotherapy induced neutropenia and anemia, bone metastasis, hair loss, etc.

City firefighter dies of cancer related to the line of duty

Funeral services as set for this Friday for the Lethbridge Fire Department Captain John Wagontall who died on Sunday after a battle with cancer related to the work of firefighting. Herald file photo by Ian Martens @IMartensHerald In 2006, he rode nearly 8,000 kilometres across Canada during a Cycle For Life campaign, raising awareness about prostate cancer and the importance of early detection – and raising almost $25,000.

Health Highlights: Dec. 20, 2016

The therapy features lasers and a drug made from deep sea bacteria, and does not cause severe side effects, BBC News reported. A clinical trial of 413 prostate cancer patients at 47 hospitals across Europe found that 49 percent had no remaining trace of cancer after undergoing the treatment.